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Abstract
Objective—Avidin exhibits ideal characteristics for targeted intra-cartilage drug delivery: its 
small size and optimal positive charge enable rapid penetration through full-thickness cartilage 
and electrostatic binding interactions that give long half-lives in-vivo. Here we conjugated Avidin 
with dexamethasone (DEX) and tested the hypothesis that single-dose Avidin-delivered DEX can 
ameliorate catabolic effects in cytokine-challenged cartilage relevant to post-traumatic OA.
Methods—Avidin was covalently conjugated with DEX using fast (ester) and slow, pH-sensitive 
release (hydrazone) linkers. DEX release kinetics from these conjugates was characterized 
using 3H-DEX-Avidin (scintillation counting). Cartilage explants treated with IL-1α were cultured 
with or without Avidin-DEX conjugates and compared to soluble DEX. Sulfated-
glycosaminoglycan (sGAG) loss and biosynthesis rates were measured using DMMB assay 
and 35S-incorporation, respectively. Chondrocyte viability was measured using fluorescence 
staining.
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Results—Ester linker released DEX from Avidin significantly faster than hydrazone under 
physiological buffer conditions. Single dose Avidin-DEX suppressed cytokine-induced sGAG loss 
over 3-weeks, rescued IL-1α-induced cell death, and restored sGAG synthesis levels without 
causing cytotoxicity. The two Avidin-DEX conjugates in 1:1 combination (fast:slow) had the most 
prominent bioactivity compared to single dose soluble-DEX, which had a shorter-lived effect and 
thus needed continuous replenishment throughout the culture period to ameliorate catabolic 
effects.
Conclusion—Intra-cartilage drug delivery remains inadequate as drugs rapidly clear from the 
joint, requiring multiple injections or sustained release of high doses in synovial fluid. A single 
dose of Avidin-conjugated drug enables rapid uptake and sustained delivery inside cartilage at low 
intratissue doses, and potentially can minimize unwanted drug exposure to other joint tissues.
Keywords
Avidin; electrostatic interactions; dexamethasone; intra-cartilage delivery; cartilage repair; 
cytokine
INTRODUCTION
Osteoarthritis (OA) affects individual joints making intra-articular (i.a.) therapy a desirable 
treatment option1,2, yet simple i.a. injection remains inadequate because drugs are cleared 
from the joint space rapidly via the lymphatics or vasculature3,4. Current research focuses on 
i.a. injection of drug-encapsulating micro or nanoparticles for slow release of drugs into the 
synovial fluid5–7. However, this approach does not assure penetration of drugs or drug 
carriers into the dense extracellular matrix (ECM) of cartilage unless a very high drug 
concentration is used. Such penetration is critical since the majority of chondrocytes and 
ECM targets reside in the tissue’s middle and deep zones. Thus, drug carriers intended for 
i.a. application should facilitate rapid drug transport into cartilage and remain bound within 
to achieve sustained intra-tissue therapeutic levels before they are cleared from the joint 
space.
We previously showed that such challenges of drug delivery into cartilage can be overcome 
by using cationic nanoparticles less than 10nm in diameter8. The high concentration of 
negatively charged aggrecan inside cartilage offers distinctive advantages for using 
electrostatic interactions that maximize intra-tissue transport, uptake and binding of cationic 
drug carrying particles. We used a highly basic protein, Avidin (pI 10.5, net charge +20, 
7nm diameter8), as an example of a drug carrier, and reported a six-fold upward Donnan 
partitioning factor at the synovial fluid-cartilage interface (Fig. 1). This resulted in a steep 
intra-tissue concentration gradient that significantly enhanced Avidin’s transport and uptake 
within various tissues of rabbit9 and rat knee joints in-vivo10. Non-specific electrostatic 
interactions are weak and reversible and thus allow Avidin to penetrate deep into cartilage. 
Stronger binding mechanisms can dramatically slow diffusion of drugs or drug carriers and 
limit their penetration; in contrast, Avidin exhibited weak-reversible binding with intratissue 
binding sites, allowing diffusion through full thickness of cartilage, yet having a long 
retention period due to high binding site density of negatively charged proteoglycans. 
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Importantly, Avidin demonstrated similar results even after enzymatic removal of 40% 
GAG in cartilage to mimic early changes of post-traumatic osteoarthritis (PTOA)8.
Traumatic joint injury, which progresses to PTOA with high incidence rate11, is 
characterized by transiently increased synovial fluid concentrations of pro-inflammatory 
cytokines (e.g., IL-1, IL-6 and TNFα) that are associated with cartilage ECM 
proteolysis12–14. Potential therapeutics, including anti-catabolic glucocorticoids (e.g., 
dexamethasone (DEX), triamcinolone) and pro-anabolic growth factors (e.g., IGF-1, 
FGF-18, BMP-7) are known to ameliorate cytokine-induced cartilage degradation in 
vitro15–18. DEX has been shown to suppress cytokine-induced ECM catabolism via GC 
receptor-dependent pathways16, and, together with anabolic factors (e.g., IGF-1) can 
maintain matrix biosynthesis levels18. However, in animal19–21 and human studies22, 
ineffective intratissue delivery necessitates high i.a. drug doses which, for glucocorticoids, 
can cause bone resorption and systemic organ toxicity. Thus, an effective treatment to 
prevent cartilage degradation associated with PTOA would benefit from delivery of 
sustained low drug doses inside cartilage.
The objectives of this study were to (1) devise a method to conjugate DEX to Avidin and 
quantify the release of DEX from Avidin-DEX complexes, and (2) test the ability of a single 
initial dose of Avidin-DEX to inhibit cytokine-induced ECM degradation, rescue cell 
biosynthesis rates and loss of cell viability in cartilage explants over long durations after 
penetration/binding of Avidin-DEX into cartilage (depicted schematically in Fig. 1). A 
combination of fast and slow release chemical linkers for conjugation is used to enable 
sustained release of DEX inside cartilage. We found that a single dose of Avidin-DEX 
inhibited cytokine-induced explant catabolism over 3-weeks, while a single dose of soluble 
DEX had short-lived efficacy and thus required continuous replenishment. Avidin-DEX also 
inhibited cytokine-induced loss of chondrocyte viability and rescued matrix biosynthesis 
levels. Avidin has been reported to have no adverse effects on safety in humans23,24 and no 
effects on cartilage viability or biosynthesis even at high concentrations in-vitro10. 
Nevertheless, as covalent attachment of poly(ethylene glycol) (PEG) can further shield 
potential immunogenic responses25 to highly cationic species, we conjugated PEG to Avidin 
to further ensure in-vivo compatibility.
MATERIALS AND METHODS
The chemical structures and schematics of the four configurations of Avidin-DEX 
conjugates synthesized for this study are shown in Fig. 2. Initially, DEX was 
supramolecularly encapsulated within native (Fig. 2A) and PEGylated (Fig. 2B) Avidin to 
construct a nanoscale, Avidin-based drug delivery vehicle (abbreviated as Av+DEX and 
PEG-Av+DEX, respectively). In addition, to achieve controlled release of DEX from such a 
nanoparticle delivery construct, we attached DEX to biotinylated PEG through ester (for fast 
drug release (Fig. 2C)) or hydrazone (for slower and sustained release (Fig. 2D)) linkages, 
which in turn were supramolecularly coupled to Avidin through the Avidin-biotin 
interaction. Drug release profiles from these two covalently modified constructs (PEG-Av-
ester-DEX and PEG-Av-hydrazone-DEX) were compared with their non-covalently 
constructed counterparts (Fig. 2A,B). The biological activity of these constructs was then 
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tested using an in-vitro model of cartilage catabolic injury incorporating IL-1α-treated 
cartilage explants in organ culture.
Supramolecular entrapment of Avidin with 3H-DEX (non-covalent conjugation)
All chemical compounds were purchased from Sigma Aldrich, MO unless specified. 
Compound A (Av+DEX, Fig. 2A) was synthesized by dissolving Avidin in 1xPBS and 
adding to the solution an amount of unlabeled DEX equivalent to two-times the weight of 
Avidin used, and an amount of 3H-DEX (specific radioactivity: 100Ci/mmol, concentration: 
1mCi/mL, American Radiolabeled Chemicals, MO) equivalent to a final concentration of 
5μCi/mL.
For synthesizing compound B (PEG-Av+DEX, Fig. 2B), Avidin was PEGylated utilizing its 
4 biotin binding sites by mixing 4 molar equivalents of biotinylated PEG-amine (2.3kDa) 
with 1 molar equivalent of Avidin (Invitrogen, CA) in 1xPBS at room temperature for 2.5h. 
The fluorescent probe 2,6-ANS (Invitrogen, CA) dye assay was used to confirm 
stoichiometric binding of biotinylated PEG to Avidin as described 26. Conjugation of 
biotinylated PEG to Avidin affects its relative electrophoretic mobility27; this was confirmed 
using SDS-PAGE in 4–12% separating gels (NuPAGE Novex 4–12% Bis-Tris gel System, 
Life Technologies, CA) under reducing conditions. The gels were then stained for protein 
(Coomassie brilliant blue). Similar to compound A, we added an amount of unlabeled DEX 
equivalent to two-times the weight of Avidin used, and enough 3H-DEX to yield a final 
concentration of 5μCi/mL.
The solutions (both PEGylated and native Avidin) were stirred overnight at room 
temperature, filtered (0.2μm mesh), then ultra-filtered (3.5kDa mesh, spinning at 8,000g for 
30min) to remove free DEX from the solution that was not functionalized to Avidin. The 
final DEX concentration was estimated by measuring radioactivity (microBeta TriLux liquid 
scintillation counter, Perkin Elmer). Avidin concentration was determined using the 
bicinchoninic acid (BCA) assay28. Drug loading content (DLC) of the final solutions was 
estimated by:
Synthesis of compounds C (PEG-Av-ester-DEX) and D (PEG-Av-hydrazone-DEX)
Compounds C and D (Fig. 2) were synthesized by two-step reaction protocols. In the first 
step, DEX was conjugated to biotinylated PEG through either an ester (3, Scheme-1, 
supplementary material) or a pH sensitive hydrazone linker (6, Scheme-2, supplementary 
material). In the second step, biotinylated PEG-DEX conjugate was supramolecularly 
attached to Avidin. (Synthesis steps for both ester and hydrazone linkers are described in 
Schemes-1 and -2 of supplementary material.)
In-vitro drug release
Release of DEX from Avidin-conjugated DEX compounds was measured using dialysis 
membranes (Spectra/Por Float-A-Lyzer G2) having molecular weight cutoff 3,500Da. A 
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solution of Avidin-conjugated 3H-DEX (5mL) was placed in a dialysis bag immersed in a 
flask containing 200mL of 1xPBS at pH 7.4 or 4.0 (the latter for hydrazone-linked 
conjugate; pH adjusted with 1.0N HCl) at 37°C, with continuous magnetic stirring. At 
different time intervals (starting at t=0), aliquots of solution (50μL) were withdrawn from 
inside the dialysis bag and the radioactivity measured (liquid scintillation) to estimate the 
concentration of residual 3H-DEX-Avidin in the dialysis bag. The percent 3H-DEX release 
was calculated using as follows, where t is the time at which radioactivity is measured and to 
is the initial time:
Biological response of cartilage in-vitro
Cartilage disks (3mm diam, 1mm thick) with intact superficial zone were harvested from 
femoropatellar grooves of 1–2 week old bovine calf knees (Research 87, Hopkinton, MA) as 
described8. Cartilage disks for all treatment groups were matched for depth and location 
along the joint surface. Disks were equilibrated in serum-free medium (low-glucose DMEM 
(Cellgro, VA)), 10mM HEPES buffer (Invitrogen, CA), supplemented with 1% ITS (insulin-
transferrin-selenium, 10μg/ml, 5.5μg/ml and 5ng/ml, respectively), 0.1mM nonessential 
amino acids, 0.4mM proline, 20μg/mL ascorbic acid, 100 units/mL penicillin G, 100μg/mL 
streptomycin, and 0.25μg/mL amphotericin B for two days in a 37°C, 5% CO2 incubator 
prior to treatment.
Treatment of cartilage with exogenous cytokine and soluble DEX
To establish the baseline comparison for studying the effectiveness of Avidin-DEX 
constructs, we first treated groups of cartilage explants with IL-1α (1ng/mL) for 16 days in 
the presence of the following DEX-treatment conditions: (i) single initial dose of 100nM 
soluble DEX, and (ii) continuous dose of 100nM DEX. Medium was changed every 2 days 
and IL-1α was replenished at each medium change. In the ‘single DEX dose’ condition, 
cartilage explants were subjected to DEX for only the first 2 days, and subsequent medium 
changes did not contain DEX, thereby simulating a single i.a. injection of DEX in-vivo. 
Medium for the ‘continuous DEX dose’ treatments was, however, replenished with DEX 
throughout the duration of the 16-day culture.
Treatment with Avidin covalently-conjugated DEX compounds
To determine the concentration of Avidin-conjugated DEX that would effectively suppress 
IL-1α-induced GAG loss in cartilage with only one dose added on day-0 of culture, cartilage 
explants were treated with or without IL-1α (1ng/mL) and incubated for eight days with one 
dose of increasing concentrations of PEG-Av-ester-DEX compound (DEX concentrations of 
100nM, 4μM and 100μM). Since 4 moles of DEX are covalently conjugated with 1 mole of 
Avidin using ester linker, these DEX concentrations imply Avidin loading of 25nM, 1μM 
and 25μM respectively. To test the biological effectiveness of Avidin-conjugated DEX 
compounds, we treated cartilage explants with or without IL-1α (1ng/mL) for 8, 16 or 22 
days in combination with: (i) one-time dose of Avidin-conjugated DEX using ester linker 
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(PEG-Av-ester-DEX, compound C), (ii) one time dose of Avidin-conjugated DEX using 
hydrazone linker (PEG-Av-hydrazone-DEX, compound D), (iii) one time dose of a 1:1 
molar ratio of compounds C and D, (iv) one time dose of soluble DEX. An effective 
concentration of 100μM DEX was used in all treatments.
Chondrocyte viability in explant culture with Avidin-DEX compounds
Upon termination of culture, 100–200μm thick slices were cut from the center of disks from 
each treatment condition using established methods8. Slices were immediately stained for 2–
3 minutes in the dark with Fluorescein Diacetate (FDA; 4mg/ml in PBS) and Propidium 
Iodide (PI; 40mg/ml in PBS). FDA stained viable cells green and PI stained non-viable cells 
red10. Slices were washed with PBS and imaged (Nikon fluorescence microscope; 4x 
objective).
Cartilage sGAG loss to medium and sGAG biosynthesis in cartilage
Two days before termination of 8-day cartilage cultures, the medium was supplemented with 
5 μCi/mL [35S]-sulfate (PerkinElmer, CT). After 2-day radiolabel period, explants were 
washed 4 times over 80 minutes with cold PBS to remove free label. Each individual explant 
was first weighed wet and then digested with proteinase-K (Roche, MN) overnight. 
Cumulative release of sGAG to the medium and residual sGAG in the digested explants 
were measured using the dimethyl-methylene blue (DMMB) dye binding assay29. 
Radiolabel in each digested sample and medium standards (35S) were measured (liquid 
scintillation); radiolabel concentration was calculated from the standards and normalized to 
explant wet weight.
Statistical Analysis
For all cartilage explant studies, we used the general linear mixed effects model with animal 
as a random variable, followed by Tukey’s Honestly Significant Difference test for 
comparisons between multiple treatment conditions. There was no effect of animal found 
and, hence, data across animals were pooled. P-values less than 0.05 were considered 
statistically significant.
RESULTS
Characterization of Avidin-conjugated DEX compounds
As shown in Fig. 2 the following chemical compounds of Avidin loaded DEX were 
prepared: (A) Av+DEX, (B) PEG-Av+DEX, (C) PEG-Av-ester-DEX and (D) PEG-Av-
hydrazone-DEX. Their drug loading content values (DLC, mean±SD) are reported in Table 
1. Compounds C and D have four moles of DEX covalently bound with one mole of Avidin 
using ester or hydrazone linker; thus, based on molar masses, a theoretical DLC value of 
2.3% is expected for fully conjugated Avidin. The molar ratio of biotinylated PEG to Avidin 
in compounds B–D was determined by the fluorescent probe 2,6-ANS dye assay. Addition 
of biotinylated PEG to the 2,6-ANS dye and Avidin solution displaced the ANS dye, 
resulting in reduction of fluorescence intensity with increasing molar ratio of biotinylated 
PEG to Avidin (Fig. 3A). A plateau in fluorescence value was achieved starting at 4:1 molar 
ratio of biotinylated PEG to Avidin, as expected. Conjugation of Avidin with biotinylated 
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PEG also resulted in a shift of molecular weight as observed in SDS-PAGE from the band at 
~16kDa (Fig. 3B, monomeric form of Avidin (Av lane) shifted to the broader band at higher 
MW (PEG-Av lane) due to addition of 2.3kDa PEG chains).
In-vitro DEX release from Avidin
Release profiles of 3H-DEX from non-covalent compounds in PBS at 37°C and pH 7.4 are 
shown in Fig. 4A. ~70% of loaded DEX was released from compound A (Av+DEX) in 3h. 
PEGylation of Avidin (Compound B) did not alter this release rate which was similar to 
DEX diffusivity in PBS, suggesting absence of any robust binding interaction between DEX 
and the macromolecular assembly of Avidin or PEGylated-Avidin. In contrast, conjugation 
of DEX to Avidin via ester linkage dramatically slowed the release of DEX (Fig. 4B, 
compound C), resulting in a half-life of 14.4±1h at pH 7.4 (mean life time=20.8h). This 
half-life was calculated by fitting a first order exponential decay curve to the measured 
average concentration inside the dialysis membrane versus time (inset of Fig. 4B).
Conjugation of DEX to Avidin via hydrazone linkage (compound D) slowed DEX release 
even further (Fig. 4C). The hydrazone bond underwent only limited cleavage at pH 7.4, with 
maximum release at 30% loading. This bond, however, becomes less stable in an acidic 
environment30–32. Consistent with this behavior, DEX release from hydrazone linker at pH 
4 showed a mean half-life of 57.4±3.6h. The initial fast release of DEX may be attributed to 
non-covalently bound DEX on Avidin, implying a longer half-life than 57.4h.
Avidin-DEX compounds did not affect chondrocyte viability in cartilage explants
The cytotoxicity of Avidin-DEX compounds was evaluated by assessing chondrocyte 
viability in cartilage explants using the live-dead fluorescence assay. Cartilage explants were 
treated for 48h with compounds C and D, PEG-Av-ester-DEX and PEG-Av-hydrazone-
DEX (final DEX concentration of 100μM). Representative images from 3–4 cartilage disks 
from all treatment conditions at 48h (Fig. 5B,C) showed minimal cell death and were similar 
to untreated controls (Fig. 5A). (Some cell death in the superficial zone was typically 
observed in untreated control explants, depending on the location of harvesting along the 
joint.)
Effect of single versus continuous dose of soluble DEX on IL-1α treated cartilage
As expected, IL-1α treatment caused increased loss of sGAG-containing aggrecan fragments 
from cartilage explants over 16 days compared to controls (Fig. 6, P<0.0001 all time points). 
Cumulative sGAG loss was 5–6x higher in IL-1α treated explants compared to untreated 
controls by day-16. Both single dose (day-0–2) and continuous doses (starting day-0) of 
100nM DEX inhibited sGAG loss until day-10 compared to IL-1α alone (P<0.0001). 
However, at day-12, there was a substantial increase in sGAG loss from the single DEX 
dose explant condition (P<0.0001), at the same rate as that from IL-1α treatment alone, 
while the continuous DEX dose maintained inhibition of sGAG loss at the same rate through 
day-16.
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Dose dependent bioactivity of Avidin-DEX compounds in cartilage
As shown in Fig. 6, a low but continuous dose of 100nM DEX was sufficient in suppressing 
IL-1α-induced GAG loss from cartilage explants. To determine the concentration of DEX 
from one dose of Avidin-delivered DEX that would effectively suppress GAG loss for long 
times, we tested the dose-dependent response of PEG-Avidin-ester-DEX (compound C) on 
IL-1-treated explants over 8-days (Fig. 7A). We found that one dose of all DEX 
concentrations (100nm-100μM) in compound C could suppress IL-1-induced GAG loss; 
however, the effect was most prominent using the 100μM DEX-equivalent concentration 
(Fig. 7A). Hence, a concentration of 100μM DEX delivered through Avidin conjugated 
DEX structures was chosen for subsequent experiments.
Single dose Avidin-DEX rescued cartilage GAG loss in the presence of IL-1α
Fig. 7B compares cumulative IL-1-induced GAG loss over 22-days in the presence of a 
single dose of 100μM soluble DEX versus a single dose of 100μM DEX delivered via 
Avidin (using ester and hydrazone linkers, compounds C and D). IL-1α treatment increased 
GAG loss compared to untreated controls at all time points (Fig. 7B, P<0.0001). When 
IL-1α-treated explants were incubated with a single dose of soluble DEX from day 0–2, 
GAG loss was markedly reduced (P<0.0001 compared to IL-1α alone). However, treatment 
with a single dose of compound C (PEG-Av-ester-DEX) suppressed GAG loss even further 
than soluble DEX alone (P<0.0001 compared to soluble DEX, all time points). PEG-Av-
hydrazone-DEX inhibited sGAG loss in a manner similar to soluble DEX at earlier time 
points. While soluble DEX appeared to lose its effect by day 18, PEG-Av-hydrazone-DEX 
showed more effective inhibition of sGAG loss by days-20 to 22 (P=0.038 compared to 
single dose DEX at day 22). Finally, a 1:1 molar ratio of two linker chemistries with 
effective DEX concentration of 100μM performed better than the slow-releasing hydrazone 
linker (P=0.001 at day-2, P<0.0001, subsequent time points) but similarly to ester linker 
(Fig. 7B).
Avidin-DEX rescued biosynthesis rates and chondrocyte viability in IL-1α-treated cartilage
Compared to untreated controls, sulfate incorporation was greatly suppressed by IL-1α-
treatment in bovine cartilage explants by day 8 of culture (Fig. 8A, P<0.0001). Addition of a 
single dose of 100μM soluble DEX from day 0–2 or continuous dose of soluble 100nM 
DEX increased 35S-sulfate incorporation compared to IL-1 α alone (P<0.0001). One dose of 
PEG-Av-ester-DEX and PEG-Av-hydrazone-DEX also had similar rescuing effects. In 
addition, Avidin-conjugated DEX rescued chondrocyte viability in the presence of IL-1α 
(Figs. 8Bi–vi). A dramatic increase in cell death was observed after treatment with IL-1 
alone by day-8 (Fig. 8Bii). In contrast, addition of a single dose of 100μM DEX on day 0–2 
(Fig. 8Biii) or a continuous dose of 100nM DEX (Fig. 8Biv) successfully prevented cell 
death induced by IL-1α. Treatment with a single dose of PEG-Av-ester-DEX or PEG-Av-
hydrazone-DEX (Figs. 8Bv–vi) added on day 0–2, also successfully rescued chondrocyte 
death similar to that observed using the soluble DEX conditions.
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DISCUSSION
This work demonstrates a drug delivery approach to long term suppression of cytokine-
induced loss of GAG and chondrocyte viability inside cartilage with just a single-dose 
treatment exemplified using Avidin-conjugated DEX. Avidin, due to its ideal size and 
positive charge, rapidly penetrates through full thickness cartilage due to electrostatic 
interactions and reversible binding within tissue, resulting in long half-lives in-vivo9,10. We 
used a combination of fast (ester) and slow release-pH cleavable (hydrazone) linkers to 
conjugate DEX with Avidin and compared its biological efficacy with a single dose of 
soluble DEX in an IL-1α-challenged cartilage explant model. IL-1α is one of the family of 
inflammatory cytokines that is thought to play a critical role in the initial events associated 
with progression to PTOA14 and causes GAG loss by up-regulating ADAMTS-4,5 in 
bovine33 as well as human14 cartilage. We used DEX as an example drug as it has been 
previously shown to block cytokine-induced cartilage degradation16,18.
Our data show that a single dose of DEX alone could not provide long term suppression of 
GAG loss compared to continuous DEX treatment during culture. Removal of 100nM DEX 
after day 0–2 provided inhibition of GAG loss only for the first 8 days (Fig. 6), after which 
increased aggrecan catabolism continued, such that the cumulative GAG loss by day 16 was 
1.8x higher than the continuous DEX dose condition. However only a single dose of either 
PEG-Av-ester-DEX or compound C+D (1:1 molar ratio of ester and hydrazone) added at 
day 0–2 was needed to significantly reduce IL-1-induced GAG loss compared to the soluble 
DEX condition over 3-weeks (Fig. 7B). Compound D had a similar effect as 1-dose soluble 
DEX at earlier time points, but by day-22, a significantly greater suppression of GAG loss 
was observed. In separate experiments, there was negligible uptake of Avidin by the 
chondrocytes (Fig S1 Supplementary Material). Thus, we conjugated DEX to Avidin using 
hydrolysable linkers like ester and hydrazone to facilitate release of DEX, making it 
available for uptake by chondrocytes.
The ester (compound C) is a fast-releasing linker giving a mean half-life of 14.4h at 
physiological conditions (Fig 4B), suggesting that 70% of the loaded DEX released before 
the first medium change (48h after start of culture), thereby providing an initial appropriate 
dose of DEX to chondrocytes in cartilage that is critical for inhibiting IL-1α-induced 
catabolic effects. Hydrazone is a slow releasing linker with a mean half-life of 57.4h at low 
pH4 (Fig 4C). As it cleaves in acidic environments34, hydrazone should release DEX closer 
to negatively charged GAG chains in the chondrocyte pericellular matrix (where aggrecan 
concentration is highest35). Additionally, a decrease in pH from 7.4 to 5.5 was reported at 
cartilage surfaces of OA patients4. At the micro-scale aggrecan density increases with depth 
into cartilage from the superficial zone36. Thus, as Avidin carries the drug into middle-deep 
zones of cartilage where most chondrocytes reside, the rate of drug release from hydrazone 
linker should increase with depth into cartilage. A combination of ester and hydrazone is 
expected to yield greater rescuing effect at longer times in-vivo, and this approach is 
currently being tested in a rabbit anterior cruciate ligament transection (ACLT) model of 
PTOA.
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Treatment with Avidin-DEX compounds did not cause cytotoxic effects as there was no 
effect on chondrocyte viability (Fig. 5). Both compounds rescued cytokine-induced decrease 
in biosynthesis and chondrocyte viability, similar to soluble DEX conditions (Figs. 8A–B). 
Previously, we showed that Avidin alone, up to 100μM concentration, did not affect 
chondrocyte biosynthesis of proteins and proteoglycans in similar-aged bovine cartilage 
explants10. Here, we used one dose of <25μM Avidin for delivering 100μM DEX to 
cartilage explants in low glucose medium containing 1% ITS. Therapeutic use of Avidin can 
elicit the production of anti-Avidin antibodies in-vivo23,37,38 but this has been shown to 
have no effect on its safety or efficacy in humans23,39
A limitation of this study is that experiments were performed using culture medium without 
synovial fluid (SF). Hyaluronic acid and other negatively charged moieties in SF could in 
principle lead to binding of Avidin, preventing penetration of Avidin and conjugated drugs 
into cartilage. However, as we reported previously, i.a. injection of Avidin into rabbit9 and 
rat10 knee joints in vivo resulted in Avidin penetration from knee SF into the superficial 
zone and through the full thickness of joint cartilages, as documented by confocal images10 
and by direct measurement of the half-lives of Avidin inside these knee cartilages9,10. 
Additionally, in separate tests, we observed that the release of DEX from PEG-Av-ester-
DEX and PEG-Av-hydrazone-DEX after 100 h in bovine SF in vitro is similar to that found 
in the PBS conditions of the present manuscript. We therefore suggest that Avidin-DEX 
compounds can indeed be carried into cartilage in vivo, and are currently testing this 
approach in a rabbit ACLT model.
In summary, Avidin as a nano-carrier can rapidly transport candidate DMOADs into the 
middle and deep zones of cartilage and bind reversibly inside the tissue, thereby creating a 
drug reservoir and providing sustained delivery to nearby cell and ECM targets. It is now 
accepted that multiple DMOADs may be useful for disease modification15. One example of 
such a drug combination would be a pro-anabolic growth factor (e.g., IGF-117,40) known to 
stimulate cartilage repair, and an anti-catabolic glucocorticoid (e.g., DEX18). Growth factors 
such as IGF-1 can be similarly conjugated with Avidin by using a combination of slow and 
fast drug releasing chemical linkers to enable targeted and sustained delivery inside cartilage 
along with glucocorticoids.
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Fig. 1. 
Schematic of the concept underlying the drug delivery scheme developed. (A) Avidin 
nanoparticles due to their ideal size and high positive charge can penetrate through full 
thickness of cartilage owing to weak and reversible electrostatic binding with the negatively 
charged aggrecan within cartilage. (B) A high upward Donnan partitioning factor enables 
rapid transport into and within the cartilage8. (C) A single dose of Avidin-conjugated 
dexamethasone (DEX) using fast (ester) and slow release linkers (hydrazone) enabled 
delivery of DEX to chondrocytes which suppressed cytokine-induced loss of sGAG and 
chondrocyte viability. SZ=superficial zone of cartilage, DZ=deep zone
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Fig. 2. 
Schematic representation and chemical structures of the four Avidin (Av) conjugated 
dexamethasone (DEX) compounds formulated. (A) Av+DEX: Avidin supramolecularly 
(non-covalently) loaded with DEX. (B) PEG-Av+DEX: PEGylated Avidin supramolecularly 
(non-covalently) loaded with DEX. (C) Fast release PEG-Av-ester-DEX: PEGylated Avidin 
covalently conjugated with DEX using ester linkers. (D) Slow release PEG-Av-hydrazone-
DEX: PEGylated Avidin covalently conjugated with DEX using pH sensitive hydrazone 
(HZ) linkers.
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Fig. 3. 
(A) Titration curve of 2,6 ANS-fluorometric assay for stoichiometry of biotin-PEG (2300 
Da) with Avidin in PBS buffer at pH 7.4. (B) SDS PAGE (4–12%) of Avidin (Av) and 
PEGylated Avidin (PEG Av) under reducing conditions stained with Coomassie Blue
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Fig. 4. 
(A) In vitro 3H-DEX release profiles for non-covalently DEX loaded Avidin compounds 
compared with diffusivity of 3H-DEX through the dialysis membrane in PBS (pH 7.4) at 
37°C. (B) In vitro 3H-DEX release profile for PEG-Av-ester-DEX in PBS (pH 7.4) at 37°C. 
Ester, a fast release linker, resulted in a mean half-life of 14.4h. A(t) = A0exp(−λt), where 
A(t) is the DEX concentration at time t, A0 is the initial DEX concentration inside the 
dialysis membrane at t=0 and 1/λ is the characteristic exponential decay time. The half-life 
(t1/2) is calculated as . (C) 3H-DEX release profiles for PEG-Av-hydrazone-DEX 
in PBS at 37°C at pH 7.4 (diamonds) and at pH 4 (squares). Hydrazone is an acid cleavable 
linker, and hence resulted in a slow release of DEX in acidic environment (pH 4) with a 
mean half-life of 57.4h. Data is from 4–5 DEX release experiments and are presented as 
Mean ± 95% confidence interval.
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Fig. 5. 
Images of fluorescently stained bovine cartilage explants to check for chondrocyte viability 
after 48h incubation with (A) basal media, untreated control (B) PEG Av-ester-DEX and (C) 
PEG Av-hydrazone-DEX. Effective DEX concentration of 100μM was used. Green 
indicates viable cells and red indicates non-viable cells.
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Fig. 6. 
Effect of one dose vs. continuous dose of 100nM DEX on IL-1α simulated GAG loss in 
bovine cartilage explants. Cartilage tissues were cultured with or without IL-1α (1ng/mL) 
and with one time dose of 100nM DEX or continuous dose of 100nM DEX for 16 days. 
Data are presented as Mean ± 95% confidence intervals, N=3 animals, n=6 explants for each 
treatment condition from each animal (18 explants per condition). All treatment conditions 
are significantly different from the untreated control. Error bars for the untreated control 
data points are small and thus not visible. * vs IL-1α alone, # vs one dose DEX, $ vs 
continuous dose DEX, P<0.0001.
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Fig. 7. 
(A) Effect of one dose of compound C (PEG-Av-ester DEX) on cumulative sGAG loss in 
IL-1α (1ng/ml) treated bovine cartilage explants at day 8 of culture period. Effective DEX 
concentration in these compounds is shown in brackets (100nM to 100μM). Data are 
presented as Mean ± 95% confidence interval, N=2 animals, n=6–8 explants each treatment 
condition. * vs IL-1α alone, # vs 100 μM DEX, P<0.0001
(B) Effect of one dose of effective DEX concentration of 100μM in cumulative sGAG loss 
in IL-1α (1ng/ml) treated bovine cartilage explants over a period of 22 days. One dose of 
DEX was provided in form of soluble DEX (green), compound C (PEG-Av-ester DEX, 
purple), compound D (PEG-Av-hydrazone DEX, blue) or 1:1 molar ratio of compounds C 
and D (yellow). Black line shows cumulative sGAG loss in untreated control cartilage and 
the red line shows the sGAG loss in IL-1α alone treated cartilage over a period of 22 days. 
Values are Mean ± 95% confidence interval, N=4 animals, n=6–12 explants each condition 
from each animal. All conditions are significantly different from IL-1 alone (red) at all time 
points (P<0.0001). Soluble DEX (green) and compound D (blue) are significantly different 
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from control (black) starting at day 4 (P<0.0001). Compound C (purple) and the 
combination C+D (yellow) are significantly different from control (black) starting at day 10 
(P<0.0001) and day 8 (P=0.001 at day 8 and P<0.0001 starting day 10) respectively.
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Fig. 8. 
(A) Rate of sGAG synthesis during the last 48h of the 8 days culture time period normalized 
by the wet weight of cartilage explants. Data are presented as Mean ± 95% confidence 
interval. N= 4 animals, n=6 explants each condition from each animal. * vs IL-1α alone, 
P<0.0001. One dose of compounds C, D and DEX (effective DEX concentration of 100 μM) 
are compared to continuous dose of 100nm DEX.
(B) Images of fluorescently stained bovine cartilage explants (4x objective) cultured for 8 
days to check for chondrocyte viability in (i) basal medium, untreated control (ii) treated 
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with 1ng/ml of IL-1α alone. The following conditions were treated with IL-1α (1ng/ml) 
along with (iii) 1 dose of 100μM soluble DEX (iv) continuous dose of 100nM soluble DEX 
during 8 days of culture (v) 1 dose of PEG-Av-ester-DEX and (vi) 1 dose of PEG-Av-
hydrazone (HZ)-DEX (final DEX concentration of 100μM in (v) and (vi)). Green indicates 
viable cells and red indicates non-viable cells. The top edge of each image (arrow) shows 
the superficial zone and the bottom represents the transected middle/deep zone. Scale bar 
=200μm
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Scheme 1. 
Steps of synthesis for covalent conjugation of Avidin with PEGylated dexamethasone using 
ester linker
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Scheme 2. 
Steps of synthesis for covalent conjugation of Avidin with PEGylated dexamethasone using 
hydrazone linker
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Table 1
Drug loading content (Mean+/−SD) for Avidin conjugated DEX compounds
Compound Compound type DLC (wt%)
A Av + DEX 33.2 ± 4.8
B PEG-Av + DEX 32.8 ± 3.6
C PEG-Av-ester-DEX 2.2 ± 0.3
D PEG-Av-hydrazone-DEX 1.9 ± 0.1
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